Varenicline Treatment for Cannabis Use Disorder

Substance Use Disorder Clinical Trial

Official title:

Advancing Varenicline as a Treatment for Cannabis Use Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02892110
• Other study ID #: Pro00058198
• Secondary ID: UG3DA043231
• Status: Completed
• Phase: Phase 2
• Start date: February 13, 2017
• Est. completion date: November 27, 2018

Study information

• Verified date: October 2019
• Source: Medical University of South Carolina
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Marijuana is the most commonly used illicit drug. There is high demand for effective interventions for cannabis use disorder, yet few specific treatments for have been developed. This study will evaluate the efficacy of varenicline for reducing marijuana use in people who use marijuana frequently.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 72
• Est. completion date: November 27, 2018
• Est. primary completion date: November 8, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

General Inclusion Criteria

• Must meet DSM-5 criteria for cannabis use disorder and use cannabis at least 3 days per week in the last 30 days.

• Must be between the ages of 18 and 65 years.

• If female and of childbearing potential, must agree to use acceptable methods of birth control for the duration of the trial.

• Must consent to random assignment, and be willing to commit to medication ingestion.

• Must be able to read and provide informed consent.

• Must have body weight >110lbs (50kg) and have BMI between 18 and 35kg/m2

• Must function at an intellectual level and have knowledge of the English language to sufficiently allow for accurate completion of assessments.

Additional Inclusion Criteria for fMRI Eligibility

• Must be right-handed.

General Exclusion Criteria

• Women who are pregnant, nursing, or plan to become pregnant during the course of the study.

• Individuals with severe renal impairment (creatinine clearance less than 30 mL per minute).

• Lifetime history of DSM-5 Bipolar I or II Disorder, Schizophrenia or other psychotic disorder. Stably treated MDD, Dysthymia, GAD, Social Phobia, and Specific Phobia diagnoses are acceptable (i.e. same dose of medication has been prescribed for at least 2 months prior to screening and no changes in current medication expected during course of the trial).

• Suicidal ideation or behavior within the past 6 months. Subjects who are believed to be at suicidal or homicidal risk (answers 'yes' on questions 4 or 5 of C-SSRS) will be referred for assessment by a qualified mental health professional.

• Concomitant use of psychotropic medications, with the exception of stable doses (defined as no dosing adjustments in the past two months) of non-MAO-I antidepressants, non-benzodiazepine anxiolytics, and ADHD medications.

• Current use of medications prescribed for mania or psychosis.

• Current use of buproprion or nortryptiline.

• Moderate or severe non-cannabis substance use disorders within the past 60 days with the exception of tobacco use disorder.

• Individuals taking an investigational agent within the last 30 days before baseline visit.

• Individuals with clinically significant medical disorders or lab abnormalities.

• Any individual at screening with SGOT (AST) or SGPT (ALT) greater than 3 times the upper limit of normal and/or total bilirubin greater than two times the upper limit of normal.

• Individuals with clinically significant cardiovascular disease in the past 6 months (e.g., myocardial infarction, CABG, PTCA, severe or unstable angina, serious arrhythmia, or any clinically significant ECG conduction abnormality.

• Individuals with clinically significant cerebrovascular disease in the past 6 months such as TIA, CVA, or stroke.

• Hypersensitivity to varenicline.

• Individuals who have participated in the clinical trial of any investigative compound within the last 60 days.

Additional Exclusion Criteria for fMRI Eligibility

• Any psychiatric or medical issues, including claustrophobia, ferrous metal implants, pacemakers, or other electronic devices that would interfere with ability to participate in and successfully complete scanning procedures.

• Any person unable to lie still within the fMRI scanner for the required period of time to obtain useful images (use of anxiolytics will not be permitted for anxiety/claustrophobia related to scanning procedures).

Related Conditions & MeSH terms

• Substance Use Disorder
• Substance-Related Disorders

Intervention

Drug:
• Varenicline
2 mg daily
• Placebo
2 mg daily

Locations

Country	Name	City	State
United States	Medical University of South Carolina	Charleston	South Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Medical University of South Carolina	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cannabis Withdrawal Symptoms During Active Treatment	For this outcome, the negative affect subscale items of The Cannabis Withdrawal Scale (items 5 ["I felt nervous], 6 ["I had some angry outbursts"], 7 ["I had mood swings"], 8 ["I felt depressed"], 9 ["I was easily irritated"], 15 ["Life seemed an uphill struggle"], 18 ["I felt physically tense"], restlessness (item 11, "I felt restless), and/or urge to smoke (items 1 and 10, "The only thing I could think about was smoking some cannabis" and "I had been imagining being stoned") were averaged at Weeks 4, 5, and 6 and for an overall 4-6 week value, with minimum score of the subscale being 0 and maximum score being 100 (higher score indicating worse outcome).	3 weeks (Week 4-6 of active treatment period)
Secondary	Number of Participants With Cannabis Abstinence	Self reported abstinence from Timeline Followback, verified by urine cannabinoid measures	3 weeks (Week 4-6 of active treatment period)
Secondary	Cannabis Use Quantity	Cannabis use sessions per day measured by Timeline Followback (self-report) at twice weekly visits during Weeks 4, 5 and 6 of the active treatment phase.	3 weeks (Week 4-6 of active treatment period)